… Stephanie M. de Boer … Indications for adjuvant treatment are currently based on well-established
clinicopathological risk factors such as Federation Internationale de Gynecolgie et d'…

Background Although women with endometrial cancer generally have a favourable prognosis,
those with high-risk disease features are at increased risk of recurrence. The PORTEC-3 …

Background The PORTEC-3 trial investigated the benefit of combined adjuvant chemotherapy
and radiotherapy versus pelvic radiotherapy alone for women with high-risk endometrial …

Background Risk-assessment of endometrial cancer (EC) is based on clinicopathological
factors and molecular subgroup. It is unclear whether adding hormone receptor expression, …

B-cells play a key role in cancer suppression, particularly when aggregated in tertiary lymphoid
structures (TLS). Here, we investigate the role of B-cells and TLS in endometrial cancer (…

Background About 15% of patients with endometrial cancer have high-risk features and are
at increased risk of distant metastases and endometrial cancer-related death. We designed …

Standard molecular classification of endometrial cancers (EC) is now endorsed by the WHO
and identifies p53-abnormal (p53abn) EC as the subgroup with the poorest prognosis and …

Background Endometrial cancer can be molecularly classified into POLE mut , mismatch
repair deficient (MMRd), p53 abnormal (p53abn), and no specific molecular profile (NSMP) …

Purpose To evaluate the long-term health-related quality of life (HRQL) after external beam
radiation therapy (EBRT) or vaginal brachytherapy (VBT) among PORTEC-2 trial patients, …

PURPOSE The molecular classification of endometrial cancer (EC) has proven to have
prognostic value and is predictive of response to adjuvant chemotherapy. Here, we investigate its …